Ne0hritic vs nephritic syndrome

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Excellent - I now have comprehensive data from multiple authoritative sources. Here is the full comparison:

Nephrotic Syndrome vs. Nephritic Syndrome

These are the two cardinal presentations of glomerular disease. The distinction is fundamental: nephrotic reflects a permeability failure (protein leaks out), while nephritic reflects inflammation (cells and blood leak in).

Core Pathophysiology

Nephrotic Syndrome

The glomerular capillary wall - composed of endothelium, GBM, and podocytes - acts as both a size and charge barrier. In nephrotic syndrome, structural or physicochemical alterations in this barrier increase permeability to plasma proteins. The key proteins lost are albumin, immunoglobulins, antithrombin III, and lipid-binding proteins. Podocyte injury (foot process effacement) is the common final pathway regardless of the underlying cause.

Cascade of consequences:

Massive proteinuria (≥3.5 g/day in adults; >50 mg/kg/day in children) → hypoalbuminemia (albumin <3 g/dL)
Hypoalbuminemia → reduced plasma oncotic pressure → fluid shifts into the interstitium → edema
Compensatory hepatic lipoprotein synthesis ↑ + reduced lipid catabolism → hyperlipidemia → lipiduria (oval fat bodies in urine)
Loss of immunoglobulins → susceptibility to infection (especially pneumococcal, staphylococcal)
Loss of antithrombin III + protein C/S → hypercoagulable state → renal vein thrombosis (especially in membranous nephropathy)

Two edema subtypes:

Underfill (classic, e.g., minimal change disease): low plasma volume → activated RAAS, elevated aldosterone/ADH, low ANP → sodium retention
Overfill (other causes): primary renal sodium retention → expanded plasma volume, suppressed RAAS

Nephritic Syndrome

Nephritic syndrome results from glomerular inflammation - proliferation of glomerular cells + infiltration of leukocytes. This inflammatory reaction damages capillary walls, permitting blood to enter the urine, and reduces GFR by reducing the filtering surface area. The reduced GFR leads to oliguria, fluid/sodium retention, and renin release from ischemic kidneys.

Clinical & Lab Features - Head to Head

Feature	Nephrotic	Nephritic
Onset	Insidious	Abrupt
Mechanism	Increased GBM permeability	Glomerular inflammation
Proteinuria	Massive (>3.5 g/day)	Mild-moderate (<3.5 g/day)
Hematuria	Absent or microscopic	Prominent (gross or microscopic)
RBC casts	Absent	Present (pathognomonic)
Serum albumin	Low (<3 g/dL)	Normal or slightly reduced
Edema	Severe, soft, pitting, periorbital	Mild-moderate
Blood pressure	Normal	Raised (hypertension)
JVP	Normal/low	Raised
GFR/azotemia	Usually preserved initially	Reduced, oliguria, azotemia
Urine color	Frothy (protein)	Smoky/brown (blood)
Lipids	Hyperlipidemia + lipiduria	Normal
Complement	Usually normal (except MPGN)	Often low (C3 low in PSAGN)

Urinary Findings

Finding	Nephrotic	Nephritic
Protein	+++++	++
RBCs	Rare	+++
RBC casts	No	Yes
WBCs	No	Possible
Oval fat bodies	Yes (lipiduria)	No
Fatty casts	Yes	No

Causes

Nephrotic Syndrome Causes (Robbins 9e)

Primary (children vs. adults):

Disease	Children	Adults
Minimal change disease (MCD)	75%	8%
Focal segmental glomerulosclerosis (FSGS)	10%	35%
Membranous nephropathy	3%	30%
MPGN	10%	10%

Secondary (systemic diseases):

Diabetes mellitus (most common worldwide)
Amyloidosis
Systemic lupus erythematosus (class V lupus nephritis)
Drugs (NSAIDs, gold, penicillamine, heroin)
Infections (hepatitis B, HIV, malaria)

Nephritic Syndrome Causes

Disease	Key Feature
Post-streptococcal GN (PSAGN)	Latency 1-4 wks; subepithelial "humps" on EM; ↓C3
IgA nephropathy (Berger's)	Episodic hematuria with URI; mesangial IgA deposits
Lupus nephritis (class III/IV)	Anti-dsDNA, ↓C3/C4
ANCA-associated vasculitis (GPA, MPA)	pANCA/cANCA positive; pauci-immune
Anti-GBM disease (Goodpasture's)	Linear IgG on IF; pulmonary hemorrhage
MPGN	Can present as either nephrotic or nephritic; ↓C3

Rapidly Progressive GN (RPGN) - The Nephritic Emergency

When nephritic syndrome progresses to kidney failure over days to weeks, this is RPGN. The histologic hallmark is crescents - proliferation of parietal epithelial cells in Bowman's space due to GBM breaks and fibrin leakage. Three immunologic types:

Type	Mechanism	IF Pattern	Serology
Type I	Anti-GBM antibodies	Linear IgG	Anti-GBM Ab
Type II	Immune complex	Granular ("lumpy-bumpy")	Varies (ANA, ASOT, ↓C3)
Type III	Pauci-immune (ANCA)	Negative / trace	ANCA positive

Edema Mechanism Comparison

Nephrotic underfill vs. overfill:

Nephrotic syndrome underfill vs overfill edema mechanisms

In the underfill group (typical of minimal change disease): low serum albumin → low oncotic pressure → contracted plasma volume → RAAS activation, elevated aldosterone, AVP, catecholamines, low ANP.

In the overfill group: primary renal sodium retention → expanded plasma volume → suppressed RAAS, low aldosterone. Diuretics in the underfill group risk azotemia and orthostasis; in the overfill group they work safely.

Key Memory Anchors

Clue	Think
Frothy urine, periorbital puffiness, no hematuria	Nephrotic
Cola/tea-colored urine, hypertension, oliguria	Nephritic
Child with MCD	Nephrotic, steroid-responsive
Diabetic for 10+ years with proteinuria	Secondary nephrotic
Post-sore throat hematuria in child, ↓C3	Post-streptococcal (nephritic)
Recurrent hematuria with upper respiratory infections	IgA nephropathy (nephritic)
Hemoptysis + hematuria, anti-GBM+	Goodpasture's (nephritic/RPGN)
Rapidly deteriorating kidney function with crescents	RPGN
Can present as EITHER	MPGN

Note: Some diseases - especially MPGN and lupus nephritis - blur the boundary and can present with mixed features of both syndromes simultaneously.

Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease, 10e; Comprehensive Clinical Nephrology, 7e; Brenner and Rector's The Kidney, 2-Volume Set.

Create a clinical decision tree to differentiate these syndromes

Running Command

Writing File

Running Command

Reading File

Editing File

Writing File

Running Command

Reading File

Running Command

Reading File

Running Command

Your clinical decision tree is ready:

Nephro Decision Tree
PDF Document · PDF
- A3 landscape, print-ready

Here's what the tree covers, step by step:

Entry point: Patient with suspected glomerular disease

Branch 1 - Proteinuria ≥ 3.5 g/day?

YES → Nephrotic pathway (green)
NO / sub-nephrotic → Nephritic pathway (red)

Nephrotic branch (left, green):

RBC casts / gross hematuria? → YES = mixed features (MPGN / Lupus, purple)
Albumin < 3 g/dL + hyperlipidemia? → NO = re-evaluate orthostatic/overflow proteinuria
C3 low / MPGN pattern? → YES = MPGN / Dense Deposit Disease
Age split: Children (<16) → MCD 75%, FSGS 10% | Adults → FSGS 35%, Membranous 30%

Nephritic branch (right, red):

Hematuria + azotemia? → NO = non-glomerular, further workup
Hypertension + ↓GFR / oliguria? → NO = mild nephritic (IgA / thin GBM)
Cr doubles in < 3 months? → NO = Classic nephritic (Post-strep GN, IgA, Lupus III/IV, ANCA)
YES → RPGN / Crescentic GN (orange), split into:
- Type I: Anti-GBM (Goodpasture) - linear IgG
- Type II: Immune complex - granular IF, ↓C3/C4
- Type III: Pauci-immune (ANCA) - negative IF

Footer bar: Nephrotic complications vs. Nephritic complications side by side.

Gonadal hormones drugs pharmacology and medicine

Reading File

Finding Sources

Reading File

I now have comprehensive data from Goodman & Gilman's across all major drug classes. Let me compile the full answer:

Gonadal Hormones: Drugs, Pharmacology & Medicine

(Based on Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14e)

Overview: The HPG Axis - Pharmacological Control Points

The hypothalamic-pituitary-gonadal (HPG) axis provides multiple drug targets:

Hypothalamus → GnRH (pulsatile)
      ↓
Anterior pituitary → FSH + LH
      ↓
Gonads → Estradiol / Progesterone / Testosterone
      ↓
Target tissues (ER / PR / AR)
      ↓ (negative feedback)

Drugs act at every level: GnRH analogues, gonadotropins, sex steroid agonists/antagonists, receptor modulators, and enzyme inhibitors.

I. ESTROGENS

Chemistry & Classification

Class	Examples
Steroidal (natural)	Estradiol (17β-estradiol), estrone, estriol
Steroidal (synthetic)	Ethinyl estradiol, mestranol, estradiol valerate/cypionate
Nonsteroidal synthetic	Diethylstilbestrol (DES)
Conjugated equine estrogens (CEE)	Premarin - mixture of sulfated estrogens

Mechanism of Action

Estrogens act via two nuclear receptors - ERα and ERβ - which function as ligand-activated transcription factors. The ER-ligand complex dimerizes, binds estrogen response elements (EREs) in gene promoters, and recruits co-activators/co-repressors. Non-genomic signaling also occurs via membrane-associated ERs (rapid effects on ion channels, kinase cascades).

Pharmacokinetics

Oral estradiol undergoes extensive first-pass hepatic metabolism → converted to estrone and estrone sulfate
Ethinyl estradiol: synthetic, highly resistant to first-pass metabolism → far more potent orally than natural estradiol
0.625 mg conjugated estrogens ≈ 5-10 μg ethinyl estradiol (in terms of oral potency)
Routes: oral, transdermal patch/gel, vaginal ring/cream, IM injection (esters)
Transdermal avoids first-pass effect → lower hepatic impact on clotting factors and SHBG

Physiological Effects

Secondary sexual development in females (puberty)
Endometrial proliferation (→ requires progestin opposition to prevent hyperplasia/cancer)
Bone: inhibits osteoclast activity → maintains bone mineral density
Cardiovascular: favorable lipid profile (↑HDL, ↓LDL); complex vascular effects
CNS: influences thermoregulation (hot flashes when deficient), mood, cognition
Liver: stimulates synthesis of clotting factors, SHBG, angiotensinogen, triglycerides

Therapeutic Uses

1. Menopausal Hormone Therapy (MHT)

Vasomotor symptoms (hot flashes, sweats) - most efficacious treatment
Urogenital atrophy (vaginal dryness, dyspareunia)
Osteoporosis prevention (reduces fracture risk)
Women with intact uterus: must add progestin to prevent endometrial cancer
Women post-hysterectomy: estrogen alone is appropriate
Principle: minimum effective dose for shortest necessary duration

2. Oral Contraceptives (see Section IV below)

3. Female hypogonadism - primary ovarian insufficiency, Turner syndrome

4. Transgender hormone therapy (male-to-female)

Adverse Effects

Thromboembolism (DVT, PE) - oral > transdermal; related to hepatic effect on clotting factors
Endometrial cancer (unopposed estrogen)
Breast cancer (long-term combination MHT - WHI trial data)
Migraine exacerbation
Nausea, fluid retention
Hypertriglyceridemia (oral route)
Contraindicated in: active thromboembolism, hormone-sensitive cancers, unexplained vaginal bleeding, active liver disease, pregnancy

II. PROGESTINS (Progestogens)

Classification

Class	Key Drugs	Notes
Pregnanes	Progesterone (natural), MPA (medroxyprogesterone acetate), dydrogesterone	Progesterone has rapid first-pass metabolism; micronized form available
Estranes (19-nortestosterone)	Norethindrone, norethynodrel	Some androgenic activity
Gonanes (19-nortestosterone)	Levonorgestrel, norgestrel, norgestimate, desogestrel	Progestational; components of contraceptives
Spirolactone-derived	Drospirenone	Antimineralocorticoid activity; used in OCs
Antiprogestins/modulators	Mifepristone, ulipristal	See below

Mechanism of Action

Bind progesterone receptors (PR-A and PR-B) → nuclear transcription regulation. Oppose estrogen-driven endometrial proliferation → converts proliferative to secretory endometrium. In sufficient doses, suppress LH surge → prevent ovulation.

Key Uses

MHT - endometrial protection (any woman with a uterus on estrogen must have progestin added)
Contraception (oral, injectable, implant, IUD, emergency)
Assisted reproductive technology (luteal phase support)
Endometriosis (depot MPA suppresses menstruation/lesions)
Dysfunctional uterine bleeding
Threatened/habitual abortion (progesterone support)

Key Drugs in Detail

Medroxyprogesterone acetate (MPA / Depo-Provera)

Depot IM injection (150 mg every 3 months) - highly effective contraceptive
Suppresses ovarian function → amenorrhea common
Caution: delayed return of fertility (6-18 months); transient bone mineral density loss

Levonorgestrel

Emergency contraception (Plan B): 1.5 mg within 72 h of unprotected sex
Progestin-only pill ("mini-pill")
IUD (Mirena): local uterine delivery, minimal systemic absorption

Micronized progesterone (Prometrium)

Bioidentical; preferred by many over synthetic progestins for MHT
Oral or vaginal; better tolerated (less androgenic/glucocorticoid effects)

Mifepristone (RU-486)

Competitive antagonist at both PR isoforms (also anti-glucocorticoid at high doses)
Medical abortion: combined with misoprostol (PGE1 analogue) for termination up to 10 weeks
Also used for Cushing's syndrome (mifepristone blocks glucocorticoid receptor)

Ulipristal Acetate

Partial PR agonist/antagonist
Emergency contraception up to 120 h (5 days) post-intercourse - more effective than levonorgestrel, especially days 3-5

III. ANDROGENS

Physiology

Testosterone is the principal androgen in both men and women
Men: produced by Leydig cells (LH-stimulated); ~7 mg/day
Women: corpus luteum + adrenal cortex; ~0.25 mg/day
Precursors: androstenedione, DHEA (weak androgens, converted peripherally)
Dihydrotestosterone (DHT): formed by 5α-reductase in prostate, skin, hair follicles - more potent at AR; responsible for prostate growth, male-pattern baldness
Aromatization: testosterone → estradiol (via aromatase, in adipose/brain/bone)

Testosterone Across the Life Cycle

Stage	Level	Significance
1st trimester fetus	~250 ng/dL	Male sexual differentiation (Wolffian duct development, external genitalia)
Birth	~250 ng/dL	Brief postnatal surge
2-3 months postnatal	~250 ng/dL	"Minipuberty"
Childhood	<50 ng/dL	Minimal
Puberty (12-17 yrs)	Rising to adult levels	External genitalia growth, muscle, bone, voice, sexual hair, spermatogenesis
Adult male	300-1000 ng/dL	Maintained by HPG axis
Postpuberty deficiency	Variable	Libido ↓ (weeks), Hgb ↓ (months), bone density ↓ (1 yr), muscle loss (years)

Therapeutic Androgen Preparations

Preparation	Route	Details
Testosterone enanthate / cypionate	Deep IM injection q 1-2 weeks	Formulated in oil; wide serum fluctuations → mood/libido swings
Testosterone undecanoate	IM q 10-14 weeks or oral	Long-acting IM; oral form bypasses first-pass via lymphatics
Testosterone gel/solution (1-2%)	Transdermal daily	Stable levels; risk of transfer to others via skin contact
Testosterone patch	Transdermal daily	Skin irritation common
Buccal testosterone	Buccal mucosa twice daily	Avoids first-pass; gum irritation
Alkylated androgens (methyltestosterone, oxandrolone)	Oral	17α-alkylated - resist first-pass but hepatotoxic (peliosis hepatis, cholestasis)
Nandrolone decanoate	IM	Anabolic with lower androgenic ratio

Oral testosterone itself is ineffective due to rapid hepatic catabolism. Preparations are designed to bypass this.

Therapeutic Uses of Androgens

Male hypogonadism (primary or secondary) - restore virilization, sexual function, energy, bone density, mood
Delayed puberty in boys - short course to initiate puberty
Female hypogonadism / low libido - low-dose supplementation
Wasting/catabolic states - HIV wasting, burns, major surgery (anabolic effect)
Aplastic anemia - stimulate erythropoiesis
Hereditary angioedema - anabolic androgens increase C1-inhibitor synthesis

Adverse Effects of Androgens

Virilization in women (acne, hirsutism, clitoromegaly, voice deepening)
Polycythemia (↑ EPO secretion)
Dyslipidemia (↓HDL, ↑LDL)
Suppression of spermatogenesis (negative HPG feedback → male contraceptive research)
Hepatotoxicity (17α-alkylated compounds)
Acne, oily skin
Prostatic growth (contraindicated in prostate cancer)
Premature epiphyseal closure if used in adolescents
Cardiovascular events (↑ RBC viscosity, dyslipidemia)

Selective Androgen Receptor Modulators (SARMs)

Tissue-selective AR agonists designed to maximize anabolic effects (muscle, bone) while minimizing androgenic effects (prostate, scalp). Currently investigational (enobosarm/ostarine most studied); none yet approved.

IV. ORAL CONTRACEPTIVES

Combined Oral Contraceptives (COCs)

Mechanism of contraceptive action (multiple):

Inhibition of LH surge → prevent ovulation (primary mechanism)
Altered cervical mucus → impairs sperm penetration
Altered endometrial receptivity → prevents implantation
Altered tubal motility

Components:

Estrogen: ethinyl estradiol (20-35 µg/day in modern pills); or estradiol valerate/estetrol in newer formulations
Progestin: varies by generation

Generation	Progestins	Notes
1st	Norethindrone, norethynodrel	Moderate androgenic activity
2nd	Levonorgestrel, norgestrel	Standard; lower VTE risk vs. 3rd/4th gen
3rd	Desogestrel, gestodene, norgestimate	Less androgenic; slightly higher VTE risk vs. 2nd gen
4th	Drospirenone, dienogest	Antimineralocorticoid (drospirenone); anti-androgenic; used in PCOS, acne

Formulations:

Monophasic: fixed estrogen + progestin dose throughout cycle
Biphasic/triphasic: varying doses to mimic natural cycle (theoretical advantage unproven)
Extended cycle / continuous (e.g., Seasonale): 84 active pills + 7 placebo → 4 periods/year
Progestin-only pill ("mini-pill"): no estrogen; mechanism mainly cervical mucus + endometrium; must be taken at precise same time daily

Non-contraceptive benefits of COCs:

Dysmenorrhea relief
Management of endometriosis
PCOS (cycle regulation, acne, hirsutism)
PMS/PMDD (drospirenone-containing)
Iron-deficiency anemia (reduced menstrual blood loss)
Reduced risk of ovarian and endometrial cancer
Acne treatment (anti-androgenic progestins)

Risks and Contraindications (WHO MEC):

VTE (absolute contraindication in history of DVT/PE; risk ×3-4 with COCs)
Arterial events: stroke, MI (risk highest with smoking + age >35)
Hypertension (can worsen; estrogen raises angiotensinogen)
Breast cancer (modest increased risk with current use)
Liver disease / hepatic adenoma
Migraine with aura (contraindication - ischemic stroke risk)
Absolute contraindications: smoking >35 yrs + age >35, active VTE, stroke/MI history, hormone-sensitive cancer, active liver disease, unexplained vaginal bleeding

V. GnRH ANALOGUES

GnRH Agonists (Paradoxically Suppress Gonadal Function)

Continuous (non-pulsatile) GnRH receptor stimulation → receptor downregulation → suppressed FSH/LH → medical castration

Drug	Route
Leuprolide (leuprorelin)	SC/IM depot (monthly, 3-monthly, 6-monthly)
Goserelin	SC implant
Buserelin, nafarelin	Intranasal
Triptorelin	IM depot

Initial "flare" effect: first 1-2 weeks → transient ↑ in FSH/LH/testosterone (important in prostate cancer - can worsen bone pain temporarily; cover with antiandrogen)

After 1-3 weeks: pituitary downregulation → sustained hypogonadotropic hypogonadal state

Uses:

Prostate cancer (androgen deprivation therapy)
Endometriosis
Uterine fibroids (leiomyomas)
Precocious puberty
Controlled ovarian hyperstimulation (IVF protocols) - used with gonadotropins to prevent premature LH surge
Breast cancer (premenopausal ER+ - ovarian suppression)
Menstrual suppression (thrombocytopenia, transsexual transitioning)

Long-term side effects: hot flashes, osteoporosis (add bisphosphonate ± add-back therapy), sexual dysfunction, fatigue, cognitive effects

GnRH Antagonists (Immediate Suppression - No Flare)

Competitive receptor antagonists → immediate ↓ FSH/LH (no flare effect)

Drug	Use
Cetrorelix, ganirelix	IVF - prevent premature LH surge
Degarelix	Prostate cancer (no flare; preferred if spinal metastases or urinary obstruction)
Elagolix	Endometriosis (oral); also used in uterine fibroids
Relugolix	Prostate cancer (oral, daily)

VI. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)

SERMs bind ERα/ERβ but have tissue-selective agonist or antagonist activity depending on the local co-regulator environment.

Drug	Breast	Bone	Uterus	Uses
Tamoxifen	Antagonist	Agonist	Agonist	Breast cancer (adjuvant + treatment); risk of endometrial cancer
Raloxifene	Antagonist	Agonist	Neutral/antagonist	Osteoporosis; breast cancer prevention; no endometrial risk
Toremifene	Antagonist	-	-	Breast cancer
Bazedoxifene	Antagonist	Agonist	Neutral	Osteoporosis prevention; paired with CEE ("TSEC" - tissue-selective estrogen complex)
Ospemifene	Neutral	-	Some agonism	Dyspareunia / HSDD (postmenopausal); oral
Clomiphene	Antagonist	-	-	Infertility (anovulation); blocks hypothalamic ER → removes negative feedback → ↑ FSH/LH

All SERMs: increased VTE risk (similar to estrogen)

Tamoxifen (key details):

Competitive inhibitor of 17β-estradiol binding to ER
In breast: net antagonist → used in ER+ breast cancer (premenopausal and postmenopausal)
In bone and liver: agonist → maintains bone density, favorable lipid effects
In uterus: agonist → endometrial hyperplasia and cancer risk (important ADR)
Metabolized by CYP2D6 to active metabolite endoxifen; CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) reduce efficacy

Fulvestrant (not a SERM - pure antagonist / SERD):

Selective Estrogen Receptor Downregulator (SERD)
Competitively binds ER → no agonist activity → promotes receptor degradation
IM monthly injection
ER+ HER2- advanced breast cancer (post-aromatase inhibitor failure)

VII. AROMATASE INHIBITORS (Estrogen Synthesis Inhibitors)

Block conversion of androgens → estrogens (aromatase = CYP19A1), primarily used in postmenopausal women (adrenal/peripheral aromatization is the main estrogen source post-menopause).

Drug	Type	Notes
Anastrozole	Non-steroidal (reversible)	Once daily oral; breast cancer adjuvant
Letrozole	Non-steroidal (reversible)	Also used for ovulation induction in PCOS
Exemestane	Steroidal (irreversible, "suicide inhibitor")	Aromatase inactivation; different resistance pattern

Uses:

Adjuvant therapy for postmenopausal ER+ breast cancer (more effective than tamoxifen postmenopausally)
Metastatic breast cancer
Letrozole: ovulation induction (increasingly first-line over clomiphene in PCOS)

ADRs: arthralgia/myalgia ("AI arthropathy"), osteoporosis (↓ estrogen → ↑ bone resorption), hot flashes, vaginal dryness; NOT suitable for premenopausal women (ovarian aromatase overwhelms inhibition unless combined with GnRH agonist)

VIII. ANTIANDROGENS

Inhibitors of Androgen Synthesis

Drug	Mechanism	Use
Ketoconazole (high dose)	Blocks multiple steroidogenic enzymes (CYP17A1)	Rapid castration (adrenal crisis risk)
Abiraterone	Selective CYP17A1 inhibitor (17α-hydroxylase + 17,20-lyase)	Castration-resistant prostate cancer; given with prednisone (prevents mineralocorticoid excess)
Finasteride	5α-reductase type II inhibitor → ↓ DHT	BPH, male-pattern baldness (Propecia)
Dutasteride	5α-reductase type I + II inhibitor → ↓ DHT more completely	BPH

Androgen Receptor Antagonists

Drug	Generation	Notes
Flutamide	1st gen	Hepatotoxic; rarely used now
Bicalutamide	2nd gen	Better tolerated; prostate cancer
Enzalutamide	3rd gen	No agonist activity; crosses BBB (seizure risk); castration-resistant prostate cancer
Apalutamide, darolutamide	3rd gen	Metastatic/non-metastatic prostate cancer; darolutamide - lower CNS penetration
Spironolactone	Non-selective (also MR antagonist)	Hirsutism in women; acne; used off-label as anti-androgen in trans women
Cyproterone acetate	Progestogenic antiandrogen	Hirsutism; trans women; not available in USA

IX. PDE5 INHIBITORS (Erectile Dysfunction)

Mechanism: Nitric oxide (NO) → guanylyl cyclase → cGMP → smooth muscle relaxation in corpus cavernosum → increased blood flow → erection. PDE5 degrades cGMP; PDE5 inhibitors prolong cGMP action.

Drug	t½	Onset	Duration	Notes
Sildenafil (Viagra)	4 h	30-60 min	12 h	Also used for pulmonary arterial hypertension; affected by food (high-fat meal delays absorption)
Vardenafil	4 h	30-60 min	10 h	Most potent PDE5 selectivity (Ki 0.1 nM)
Tadalafil (Cialis)	17.5 h	30-120 min	36 h	"Weekend pill"; also used for BPH; not affected by food
Avanafil	1.3-2 h	15-30 min	6 h	Fastest onset; least food effect

Critical drug interaction: Absolute contraindication with organic nitrates (both raise cGMP/cGMP-dependent pathways → catastrophic hypotension). Also caution with α-blockers.

ADRs: Headache, flushing, dyspepsia, nasal congestion, visual disturbances (sildenafil/vardenafil - PDE6 inhibition in retina), priapism (>4 hours → urological emergency)

X. GONADOTROPINS

Drug	Composition	Use
FSH (follitropin α/β, urofollitropin)	Recombinant or urinary FSH	Ovulation induction (IVF); male infertility (spermatogenesis)
LH (lutropin α)	Recombinant LH	Combined with FSH in ovulation induction
hCG (choriogonadotropin)	LH-like activity	Trigger ovulation; male hypogonadism (stimulate Leydig cells); cryptorchidism
Menotropins (hMG)	FSH + LH from urinary source	Ovulation induction

Risk of ovarian hyperstimulation syndrome (OHSS) - potentially life-threatening complication of gonadotropin therapy; characterized by enlarged ovaries, ascites, pleural effusions, hemoconcentration, thrombosis.

XI. Quick Clinical Reference Summary

Drug Class	Key Drugs	Main Use	Critical ADR/Interaction
Estrogens	Estradiol, ethinyl estradiol, CEE	MHT, contraception	VTE, endometrial Ca (unopposed)
Progestins	Progesterone, MPA, levonorgestrel	MHT, contraception, ART	Mood changes, irregular bleeding, thrombosis
Combined OC	Ethinyl estradiol + progestin	Contraception	VTE, migraine with aura
GnRH agonists	Leuprolide, goserelin	Prostate Ca, endometriosis	Flare effect, osteoporosis
GnRH antagonists	Degarelix, elagolix	Prostate Ca, endo	Osteoporosis (no flare)
SERMs	Tamoxifen, raloxifene	Breast Ca, osteoporosis	VTE; tamoxifen → endometrial Ca
SERDs	Fulvestrant	ER+ breast Ca	IM only; injection site reactions
Aromatase inhibitors	Anastrozole, letrozole, exemestane	Postmeno breast Ca	Arthralgia, osteoporosis
Androgens	Testosterone (various forms)	Male hypogonadism	Polycythemia, virilization, suppressed spermatogenesis
Antiandrogens	Enzalutamide, abiraterone, finasteride	Prostate Ca, BPH, hirsutism	Abiraterone: mineralocorticoid excess
Mifepristone	Mifepristone	Medical abortion	Anti-glucocorticoid at high doses
PDE5 inhibitors	Sildenafil, tadalafil	Erectile dysfunction, PAH	Nitrate contraindication, priapism
Gonadotropins	FSH, hCG	ART, hypogonadism	OHSS

Source: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14e - Chapter 49 (Estrogens, Progestins, Androgens) and Chapter 48 (SERMs, aromatase inhibitors)

Needle stick injury microbiology

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive, multi-source data. Here is the complete answer:

Needlestick Injury - Microbiology & Management

What Is a Needlestick Injury?

A needlestick (percutaneous sharps) injury is accidental puncture of the skin by a needle or other sharp instrument contaminated with blood or body fluid. An estimated 600,000-800,000 needlestick injuries occur annually in the US among healthcare workers. The three principal bloodborne pathogens of concern are HIV, HBV (Hepatitis B), and HCV (Hepatitis C).

The Three Key Pathogens

1. Hepatitis B Virus (HBV)

Organism: Hepadnaviridae family; partially double-stranded circular DNA virus. Serological markers:

HBsAg - surface antigen; marker of infection
HBeAg - "e" antigen; marker of active viral replication and HIGH infectivity
Anti-HBs - protective antibody; marker of immunity (vaccination or recovery)

Environmental survival: HBV retains infectivity at room temperature for at least 7 days after drying on surfaces - the most environmentally stable of the three bloodborne pathogens.

Transmission risk after needlestick:

Source Status	Risk of Clinical Hepatitis	Risk of Seroconversion
HBsAg+ AND HBeAg+ (high viremia)	22-31%	37-62%
HBsAg+ but HBeAg- (low viremia)	1-6%	23-37%
HBsAg-	Negligible	Negligible

HBV has the highest per-exposure transmission risk of all three bloodborne pathogens after needlestick.

2. Hepatitis C Virus (HCV)

Organism: Flaviviridae family; single-stranded positive-sense RNA virus. 6 major genotypes (1-6); genotype 1 predominant in USA.

Transmission risk after needlestick:

Average seroconversion rate: ~1.8% (range 0-7%)
Risk factors for transmission:
- Deep injury
- Hollow-bore needle (carries larger blood volume)
- Visible blood on needle
- High source viral load

Note: HCV is not transmitted efficiently by needlestick compared to HBV, but is far more likely to establish chronic infection (55-85% chronicity rate) compared to HBV (5-10% in adults).

3. Human Immunodeficiency Virus (HIV)

Organism: Retroviridae, subfamily Lentiviridae; single-stranded RNA virus with reverse transcriptase. Tropism for CD4+ T-helper cells and macrophages.

Transmission risk after needlestick:

Route	Risk per Exposure
Percutaneous (needlestick) from known HIV+ source	~0.3%
Mucous membrane splash	~0.09%
Non-intact skin	<0.09%
Intact skin	Negligible

Factors that increase HIV transmission risk:

Large volume of blood (visible blood contamination on device)
Deep injury
Device placed directly in vein or artery
High source viral load / advanced AIDS (source patient dying within 2 months of exposure)
Prolonged contact

Contrast: HBV (22-31%) > HCV (1.8%) > HIV (0.3%) - HBV is the most transmissible by needlestick by far.

Other Pathogens (Less Common)

Pathogen	Notes
HDV (Hepatitis D)	Only infects HBsAg-positive individuals (requires HBV co-infection); PEP same as HBV
HTLV-1/2	Rare occupational transmission reported
Malaria	Rare case reports
Syphilis	Theoretical; Treponema pallidum very fragile outside host
Tetanus	Especially with soil/dirt-contaminated needles found in community settings

Immediate Management Steps (Universal for All Needlestick Injuries)

Step 1: First Aid (IMMEDIATE)

Do not squeeze or suck the wound
Wash thoroughly with soap and water for a minimum of 15 minutes
For mucous membrane splashes (eyes, mouth): irrigate copiously with water/saline
Allow the wound to bleed freely

Step 2: Report & Assess (Within Hours)

Report to supervisor immediately
Document: time/date, type of sharp, activity being performed, site and depth of injury, source patient details
Test the source patient (with consent where applicable) for:
- HIV (rapid antibody/antigen test)
- HBsAg (Hepatitis B surface antigen)
- Anti-HCV (Hepatitis C antibody)
Test the exposed healthcare worker (baseline) for:
- HIV (antibody/antigen)
- Anti-HCV
- Anti-HBs (Hepatitis B surface antibody - to assess immunity)
- HBsAg
Review vaccination history (especially HBV)
Consider tetanus prophylaxis based on vaccination status and wound type

Pathogen-Specific Post-Exposure Prophylaxis (PEP)

Hepatitis B PEP

Management depends on the exposed worker's vaccination/immune status and the source's HBsAg status:

Exposed Worker's Status	Source HBsAg+	Source HBsAg-	Source Unknown
Unvaccinated	HBIG × 1 dose (0.06 mL/kg IM) + start HBV vaccine series	Start HBV vaccine series	Start HBV vaccine series
Vaccinated - known responder (anti-HBs ≥10 mIU/mL)	No treatment	No treatment	No treatment
Vaccinated - known non-responder	HBIG × 1 + start vaccine series OR HBIG × 2 doses	No treatment	HBIG × 1 + start vaccine series or HBIG × 2
Vaccinated - antibody response unknown	Test anti-HBs: if <10 → HBIG × 1 + vaccine booster; if ≥10 → no treatment	No treatment	Test anti-HBs; if <10 → vaccine booster; recheck in 1-2 weeks

Key points:

HBIG and HBV vaccine can be given simultaneously at different anatomical sites
PEP should be administered as soon as possible after exposure (within 24 hours ideally)
HBV vaccine series (3-dose: 0, 1, 6 months) is the best pre-exposure prevention

Hepatitis C PEP

No pharmacological PEP is currently recommended for HCV.

Management focuses on:

Baseline anti-HCV testing of exposed worker
Follow-up testing at 3-6 months for seroconversion
If source is HCV-positive: consider HCV RNA testing at 3-4 weeks post-exposure for early detection
If acute HCV infection is confirmed: refer to hepatologist - highly effective direct-acting antivirals (DAAs) can achieve sustained virological response (SVR) ≥95% even in acute phase
Treat acute HCV rather than waiting for spontaneous clearance (which occurs in ~15-45%)

HIV PEP

PEP must be initiated within 72 hours - the sooner the better (ideally within 1 hour). Efficacy diminishes significantly with delay beyond 72 hours.

Preferred PEP Regimen (US DHHS / Goldman-Cecil guidelines):

Tenofovir disoproxil fumarate (TDF) / Emtricitabine (FTC) [Truvada] + Dolutegravir (or Raltegravir)

3-drug regimen

Duration: 28 days (4 weeks)

Component	Drug	Class
Backbone	TDF/FTC (Truvada) or TAF/FTC (Descovy)	NRTI
Third agent (preferred)	Dolutegravir (DTG)	Integrase inhibitor
Third agent (alternative)	Raltegravir (RAL)	Integrase inhibitor

Follow-up testing for exposed worker:

HIV antibody/antigen at 4-6 weeks, 3 months, and 6 months
If taking PEP: monitor for drug toxicity (renal function with TDF; metabolic effects)

Important considerations:

If source patient is on antiretroviral therapy with known drug resistance, consult specialist
National Clinicians' Post-Exposure Prophylaxis Hotline: 1-888-448-4911 (24/7 consultation)
If source HIV status is unknown: assess epidemiologic likelihood and initiate PEP if high suspicion, with reassessment when source testing results return

Restrictions during follow-up period (regardless of PEP):

Refrain from donating blood, plasma, organs, tissue, or semen
No need to modify sexual practices or avoid pregnancy (exposed person is not infectious to contacts)
No specific precautions needed to prevent secondary household transmission

Community Needlestick (Non-Occupational)

Children and members of the public who sustain injuries from needles discarded in public places (parks, public toilets):

Risk is generally lower than occupational injury (older needle, less blood volume, dried)
A review of 14 studies found no transmissions among 613 children exposed to community needlesticks (for HIV, HBV, HCV)
However, every community needlestick warrants evaluation, wound care, and counseling
Tetanus prophylaxis especially important (soil/environmental contamination)
HBV PEP decision based on vaccination status
HIV PEP: based on epidemiological risk assessment (estimated prevalence of HIV among IDUs in local community)

Risk Factor Summary for High-Transmission Exposures

Transmission risk is HIGHER when:

Deep percutaneous injury (vs. superficial)
Hollow-bore needle (vs. solid suture needle)
Visible blood on device
Device placed in vein or artery (blood-filled)
Large volume of blood
High viral titer in source (HIV: advanced AIDS; HBV: HBeAg+, high DNA)
Source dies within 2 months of exposure (marker of advanced disease)

Prevention Strategies

Universal/Standard Precautions - treat all blood and body fluids as potentially infectious at all times
HBV vaccination of all healthcare workers - most effective single intervention (gives >95% seroprotection)
Safety-engineered devices - self-sheathing needles, needleless IV systems, retractable lancets
No recapping of needles - single most common activity leading to needlestick injury
Proper disposal: sharps containers - never overfill; place near point of use
PPE: gloves, eye protection, gowns when splash risk exists
Occupational health reporting systems - encourage reporting culture (many needlestick injuries go unreported)
Double-gloves during high-risk procedures (surgical, obstetric)

Comparative Transmission Risk Summary

Feature	HBV	HCV	HIV
Per-needlestick risk	22-62% (HBeAg+)	~1.8%	~0.3%
Environmental stability	Survives 7 days dry	Hours-days	Minutes-hours
Vaccine available	Yes (highly effective)	No	No
PEP available	Yes (HBIG + vaccine)	No	Yes (ARV, 28 days)
Chronicity if infected	5-10% (adults)	55-85%	100% (lifelong)
Cure possible	Functional cure (HBsAg loss)	Yes (DAAs, >95% SVR)	No (suppression only)

Sources: Yamada's Textbook of Gastroenterology 7e; Jawetz, Melnick & Adelberg's Medical Microbiology 28e; Goldman-Cecil Medicine; Harriet Lane Handbook 23e; Red Book 2021 (AAP)

This is a shared conversation. Sign in to Orris to start your own chat.